NCT00427167View on ClinicalTrials.gov

Phase I Study of AMA1-C1/Alhydrogel® (Registered Trademark) + CPG 7909 Malaria Vaccine

PHASE1CompletedINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

January 23, 2007

Primary Completion Date

November 5, 2008

Study Completion Date

November 5, 2008

Conditions
Malaria
Interventions
BIOLOGICAL

AMA1-C1/Alhydrogel + CPG 7909 (Saline)

BIOLOGICAL

AMA1-C1/Alhydrogel + CPG 7909 (Phosphate)

DRUG

AMA1-C1/Alhydrogel + CPG 7909

Trial Locations (2)

20037

Johns Hopkins University Bloomberg School of Public Health, Washington D.C.

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00427167 - Phase I Study of AMA1-C1/Alhydrogel® (Registered Trademark) + CPG 7909 Malaria Vaccine | Biotech Hunter | Biotech Hunter